| Market Capitalization (Millions $) |
219 |
| Shares
Outstanding (Millions) |
128 |
| Employees |
854 |
| Revenues (TTM) (Millions $) |
515 |
| Net Income (TTM) (Millions $) |
-10 |
| Cash Flow (TTM) (Millions $) |
-18 |
| Capital Exp. (TTM) (Millions $) |
14 |
Business Description
Organogenesis Holdings Inc is a globally recognized healthcare company that operates in the regenerative medicine and biomaterials industries. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis is committed to providing innovative solutions for wound healing, tissue regeneration, and surgical products that enhance the standard of care for patients globally.
Organogenesis Holdings focuses on developing products that are biologically-based and offer regenerative properties to promote healing and restoration of damaged tissues. The products developed by the company are based on advanced scientific research that integrates biological and physical factors to create a unique bioengineering product. The three main areas of focus for Organogenesis are Advanced Wound Care, Surgical & Sports Medicine, and Orthobiologics.
Advanced Wound Care is the primary focus of the company, and it offers an extensive product line to aid in the process of wound healing. The products developed for Advanced Wound Care include Apligraf, a bioengineered living cell product that aids in the healing of diabetic foot ulcers, venous leg ulcers, and pressure sores, and Dermagraft, a bioengineered dermal substitute that offers the ability to restore tissue for the treatment of chronic wounds.
Organogenesis Holdings aims to provide innovative surgical and sports medicine solutions for tissue repair, restoration, and healing. The company's products in this category include NuShield, a xenogenic tissue matrix that provides a barrier to soft tissue, and Allosync, a product that aids in the re-building of damaged cartilage.
Orthobiologics is a focus area of Organogenesis, and the company offers products that provide support and restoration for bone tissue. The products in this category include Gintuit, a product that is used for tissue regeneration and restoration, and NuCel, which is used for bone grafting and repair.
Organogenesis also places a great deal of focus on research and development to ensure that it remains at the forefront of the regenerative medicine industry. The company's R&D team is responsible for exploring new technologies and techniques that can be used to develop new products that offer better results to patients.
In conclusion, Organogenesis Holdings Inc is a leading healthcare company that is committed to research, development, and innovation in the regenerative medicine and biomaterials industries to ensure that it provides optimal solutions for tissue restoration and healing for patients globally.
Company Address: 85 Dan Road Canton 2021 MA
Company Phone Number: 575-0775 Stock Exchange / Ticker: NASDAQ ORGO
|
1.34% 
97.37 %